Pharmafile Logo

Rob Jones

- PMLiVE

MSD and AstraZeneca announce phase 3 results for prostate cancer therapy

The results show that the Lynparza combination therapy significantly improved radiographic progression-free survival

- PMLiVE

It’s a Medscape wrap for EHA2022

EHA2022 Hybrid Congress has now come to a close with the Thematic Days finishing last week. The Medscape team were delighted to connect with so many physicians, colleagues and supporters...

Medscape Education

- PMLiVE

Novartis publishes final positive phase 3 results of Zolgensma in Nature Medicine

Almost all children involved with copies of the SMN2 gene treated pre-symptomatically met key milestones

- PMLiVE

Research from Imperial College London shows single brain scan could diagnose Alzheimer’s disease

The new approach would allow doctors to identify the disease at an early stage and provide treatment and support to patients sooner

- PMLiVE

Shionogi, GARDP and CHAI team up to increase antibiotic access worldwide

The licence and collaboration agreements will provide 135 countries access to cefiderocol

- PMLiVE

FDA grants Pfizer/BioNTech’s COVID-19 vaccine emergency use authorisation for infants

The authorisation is specifically for the children aged six months to four years

- PMLiVE

Novartis announces promising five-year data for leukaemia treatment Kymriah

Results have shown durable remission and long-term survival in children and young adults with B-cell acute lymphoblastic leukaemia

EVOKE MIND+MATTER BROADENS STRATEGIC CAPABILITY WITH FULL-SERVICE RESEARCH & INSIGHTS OFFERING

Headed up by Research Director, Angela McMean, the Evoke Mind+Matter Insights division comprises a team of primary research specialists focused on delivering meaningful, data-driven insight that supports the agency’s mission...

Inizio

- PMLiVE

New virtual health and care report from WHO and Novartis calls for ‘critical action’

The report analysis shows how COVID-19 has changed virtual health and care policies in 23 countries

- PMLiVE

Eli Lilly’s Verzenios recommended by NICE as combination therapy for early-stage breast cancer

The trial results showed a drop of 32% in cancer recurrence when using Verzenios in combination with endocrine therapy

Subscribe to our email news alerts

Latest content

Latest intelligence

Quick links